News
Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajalle
Desentum Oy:n ("Yhtiö") yhtiöjärjestyksen 9 §:n mukaisesti osakkeenomistajille ilmoitetaan, että Suida Invest Oy on 23.9.2024 myynyt 14240 A-osaketta ("Osakkeet") STO-Rahoitus Oy:lle 2,00 euron osakekohtaiseen hintaan. Osakkeiden siirtymisestä on...
Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland
Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department...
Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen / Summons to Annual General Meeting of Desentum Oy
The shareholders of Desentum Oy are summoned to the company’s Annual General Meeting to be held on June 17th, 2024, at 14:00 (EEST) in Technopolis, Innopoli 2, Tekniikantie 14, 02150 Espoo. Meeting Room: Edison 2.
Desentum raised 12 million euros for advancing allergy vaccine development
Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj....
Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy
Desentum announces today that DM-101-C-002, a clinical study evaluating safety and tolerability of the investigational birch pollen allergy vaccine DM-101PX, has been fully recruited and the dosing of all cohorts has been started.
First subjects dosed in a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy
Desentum today announces the dosing of first subjects in a clinical study evaluating safety and tolerability of its investigational birch pollen allergy vaccine DM-101PX. The study, which is conducted in Canada, also assesses the effect of DM-101PX on allergic symptoms in a pollen exposure chamber.
Desentum received clinical trial approval from Health Canada
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical study on DM-101PX, an investigational preparation intended for immunotherapeutic treatment of birch pollen allergy. The planned study...
Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate
Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj....
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults
Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker...
Desentum in the media
Here you can find links to articles about Desentum in international media. To see articles in Finnish media, change the language to Finnish from the upper right corner.